The article PsyCap Recap: 3 Key Takeaways From the Psilera’s Presentation at Psychedelic Capital was originally published on Microdose.
Before psychedelic medicine can truly go mainstream and reach those who need it most, several hurdles must be overcome. One company in the psychedelic space working to expand access to psychedelics using novel formulations and delivery methods is Psilera Biosciences. Their novel solutions aim to bridge the gap between research and the clinic. Here are three key takeaways from their August 2021 Psychedelic Capital presentation.
Did you happen to miss this talk live at our August 2021 event, not to worry! Click here to get full access to the August PsyCap conference along with full recordings, transcripts, and AI-driven insights!
Key Takeaway #1: Psilera is Creating New Chemical Entities (NCE’s) That Are Derivatives of DMT and Psilocybin
Psilera is taking psychedelic medicine to the next level by creating NCE’s that are derivatives of DMT and Psilocybin. Not only that, but they are linking this drug development into something called the “bio receptor activity Intelligence Network” or braIN. This sophisticated program is a computational drug discovery platform that takes in data (through techniques like “protein docking”) and filters out the most optimal drug candidates.
Furthermore, it filters for those compounds that have adverse side effect profiles and off-target results. Combined with their brilliant team of formulation chemists, Psilera is ready to advance the next generation of psychedelic medicines.
Key Takeaway #2: Psilera is Helping Bring Psychedelics Into the Outpatient Setting, Allowing for Maximum Scalability
One of the biggest hurdles to scaling in-clinic psychedelic therapy, especially with traditional psychedelic compounds, is the incredible amount of time and resources it requires. By modulating activity at the serotonin 5HT2A receptor, the team at Psilera can create new psychedelic medicines with reduced, or even no psychoactivity, so they can be used in an outpatient setting. Despite their lack of psychoactivity, these new molecules aim to be equally, if not more effective and therapeutic. One of these products currently under development is a proprietary DMT transdermal patch that Psilera CEO Chris Witowski was particularly excited about. They are also working on an intranasal DMT formulation.
All in all, the efforts by the team at Psilera will help bring the benefits of psychedelic medicine into the mainstream and to those who need it most.
Key Takeaway #3: The Psilera Bioscience Team Has an Impressive Resume and Deep Drug Development Experience
Both Psilera’s CEO, Chris Witowski, and Chief Science Officer (CSO), Jackie von Salm, are dynamic PhDs with impressive resumes. Jackie is the most read author by the American Chemical Society and is particularly known for her 2017 publication showing a novel compound isolated from an Antarctic sponge. Other members of their C-suite team have worked with some of the biggest names in pharma, including Johnson & Johnson, Roache, Bristol Meyer Squibb, and more.
Their impressive backgrounds help them expand from a traditional psychedelic company into a biotech firm at the cutting edge of psychedelic science.
Closing Thoughts & A Look Ahead for Psilera Biosciences
When it comes to developing the next generation of psychedelic drugs, the team at Psilera Biosciences is making massive strides and showing good progress. From their novel psilocybin and DMT derivatives to their stellar team of scientists and C-suite executives, Psilera is definitely on the right track.nce psilocybin dmt psychedelic therapy serotonin psychedelics psychedelic capital psilera bioscience psychedelic science psilera research